First NICE summary backs tranexamic acid in trauma

摘要

EVIDENCE that tranexamic acid (Cyklokapron; Pfizer) can increase trauma patients' chances of survival has been backed by the National Institute for Health and Clinical Excellence, in its first evidence summary for unlicensed or off-label medicines. Short courses of tranexamic acid — which does not cur-rentiy have a UK marketing authorisation for use after trauma — have been shown to increase survival rates when given within eight hours of trauma to adults with severe bleeding. The finding comes from a out in 40 countries, the evidence summary says. A further analysis found it is optimal to give tranexamic acid within three hours of injury, it adds.